NCT03108066View on ClinicalTrials.gov

MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

August 30, 2023

Study Completion Date

September 27, 2023

Conditions
VHL Gene MutationVHLVHL SyndromeVHL Gene InactivationVon HippelVon Hippel-Lindau DiseaseVon Hippel's DiseaseVon Hippel-Lindau Syndrome, Modifiers ofClear Cell Renal Cell CarcinomaClear Cell RCCccRCC
Interventions
DRUG

MK-3795

800 mg twice daily (four 200 mg oral tablets twice daily)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT03108066 - MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) | Biotech Hunter | Biotech Hunter